Bicycle Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bicycle Therapeutics (BCYC).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

3S.Buy

6Buy

3Hold

Consensus RatingMarket Outperform# Analysts12Avg. Consensus PT$20Upside to Avg. PT+469.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 30, 2026	Needham	Ami Fadia	PT Cut	Buy	$15→$14
Apr 8, 2026	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$13→$12
Mar 18, 2026	Oppenheimer	Jay Olson	PT Cut	Outperform	$44→$36
Mar 18, 2026	RBC Capital	Leonid Timashev	PT Cut	Sector Perform	$11→$7
Mar 18, 2026	Citizens	Brett Knoblauch	PT Cut	Market Outperform	$12→$8
Mar 18, 2026	Needham	Ami Fadia	PT Cut	Buy	$24→$15
Nov 24, 2025	Truist Securities	Gregory Renza	Initiate	Hold	$10
Oct 31, 2025	Citizens	Reni Benjamin	PT Raise	Market Outperform	$10→$12
Oct 31, 2025	RBC Capital	Leonid Timashev	Downgrade	Outperform→Sector Perform	$27→$11
Aug 12, 2025	JMP Securities	Reni J. Benjamin	PT Cut	Market Outperform	$22→$10
Aug 12, 2025	Morgan Stanley	Jeffrey Hung	PT Cut	Equal-Weight	$17→$13
Aug 11, 2025	Oppenheimer	Jay Olson	PT Cut	Outperform	$48→$44
Jul 17, 2025	RBC Capital	Leonid Timashev	PT Cut	Outperform	$32→$25
May 6, 2025	Morgan Stanley	Jeffrey Hung	PT Raise	Equal-Weight	$15→$17
May 2, 2025	RBC Capital	Gregory Renza	PT Cut	Outperform	$35→$32
May 2, 2025	B. Riley Securities	Kalpit Patel	PT Cut	Neutral	$17→$14
May 2, 2025	JMP Securities	Reni Benjamin	PT Cut	Market Outperform	$26→$22
May 2, 2025	Needham	Ami Fadia	Maintained	Buy	$29
May 1, 2025	Barclays	Peter Lawson	PT Cut	Overweight	$40→$15
Apr 29, 2025	Needham	Ami Fadia	PT Cut	Buy	$30→$29

Analyst Ratings News

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $15 to $14.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

Morgan Stanley analyst Jeffrey Hung maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Equal-Weight and lowers the price target from $13 to $12.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

Oppenheimer analyst Jay Olson maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and lowers the price target from $44 to $36.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

RBC Capital analyst Leonid Timashev maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Sector Perform and lowers the price target from $11 to $7.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

Citizens analyst Brett Knoblauch maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Market Outperform and lowers the price target from $12 to $8.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15

Needham analyst Ami Fadia maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Buy and lowers the price target from $24 to $15.

Benzinga Newsdesk

Bicycle Therapeutics PLC

Bicycle Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

PRO
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

PRO
Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

PRO
Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

Bicycle Therapeutics PLC

Bicycle Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRONeedham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

PROMorgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

PROOppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

PRORBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

PROCitizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

PRONeedham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15

People Also Watch

People Also Watch

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $14

PRO
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12

PRO
Oppenheimer Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $36

PRO
RBC Capital Maintains Sector Perform on Bicycle Therapeutics, Lowers Price Target to $7

PRO
Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8

PRO
Needham Maintains Buy on Bicycle Therapeutics, Lowers Price Target to $15